- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
Ligand id: 4860
View more information in the IUPHAR Pharmacology Education Project: adalimumab
|No information available.|
|Summary of Clinical Use|
|Used in the management of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and plaque psoriasis.
In 2015 both the EMA and the FDA approved the use of adalimumab as a treatment for hidradenitis suppurativa, a chronic skin disease that causes abscesses and scarring on the skin.
In July 2016, the FDA expanded adalimumab approval as the first non-corticosteroid drug available for use as a treatment for non-infectious intermediate, posterior and panuveitis (forms of autoimmune-driven inflammation of the uvea)- results from Phase 3 clinical trial NCT01138657 are published in . The EMA marketing authorisation for adalimumab Trudexa® was withdrawn at the request of the marketing authorisation holder.
|Mechanism Of Action and Pharmacodynamic Effects|
|Adalimumab binds to tumor necrosis factor-alpha (TNFα), preventing it from activating TNF receptors. This action downregulates the inflammatory reactions associated with autoimmune diseases. The following references discuss adalimumab's use and action [4,9,11].|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)